- Home
- MIST vs ACET Comparison
MIST vs ACET Comparison
Compare MIST & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- ACET
- Stock Information
- Founded
- MIST 2003
- ACET 1947
- Country
- MIST Canada
- ACET United States
- Employees
- MIST N/A
- ACET N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- ACET Health Care
- Exchange
- MIST Nasdaq
- ACET Nasdaq
- Market Cap
- MIST 89.8M
- ACET 64.9M
- IPO Year
- MIST N/A
- ACET N/A
- Fundamental
- Price
- MIST $1.92
- ACET $0.62
- Analyst Decision
- MIST Strong Buy
- ACET Buy
- Analyst Count
- MIST 2
- ACET 6
- Target Price
- MIST $7.50
- ACET $6.00
- AVG Volume (30 Days)
- MIST 613.1K
- ACET 398.1K
- Earning Date
- MIST 08-07-2025
- ACET 08-12-2025
- Dividend Yield
- MIST N/A
- ACET N/A
- EPS Growth
- MIST N/A
- ACET N/A
- EPS
- MIST N/A
- ACET N/A
- Revenue
- MIST N/A
- ACET N/A
- Revenue This Year
- MIST N/A
- ACET N/A
- Revenue Next Year
- MIST N/A
- ACET N/A
- P/E Ratio
- MIST N/A
- ACET N/A
- Revenue Growth
- MIST N/A
- ACET N/A
- 52 Week Low
- MIST $0.63
- ACET $0.45
- 52 Week High
- MIST $2.75
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- MIST 67.01
- ACET 45.85
- Support Level
- MIST $1.85
- ACET $0.72
- Resistance Level
- MIST $2.02
- ACET $0.68
- Average True Range (ATR)
- MIST 0.09
- ACET 0.05
- MACD
- MIST 0.01
- ACET -0.01
- Stochastic Oscillator
- MIST 73.75
- ACET 21.21
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.